NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
01 mars 2023 11h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced a new option for patients and caregivers seeking a telehealth evaluation for the Monarch eTNS System®. NeuroSigma is a Los...
Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
12 janv. 2023 08h30 HE
|
Odyssey Health, Inc
Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
19 déc. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today...
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
23 nov. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Odyssey Health, Inc. Schedules Annual Meeting of Stockholders
15 nov. 2022 08h00 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on...
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
03 nov. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on...
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
01 nov. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), announces that it has filed for United...
Global Speech Therapy Market is Expected to Reach USD 17 Billion by 2031: Says AMR
31 oct. 2022 05h08 HE
|
Allied Market Research
Portland, OR, Oct. 31, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Speech Therapy Market was estimated at $9.9 billion in 2021 and is...
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
17 oct. 2022 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of...
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases
11 oct. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...